Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy

Leuk Lymphoma. 2019 Feb;60(2):519-522. doi: 10.1080/10428194.2018.1480775. Epub 2018 Jul 6.

Authors

Alankrita Taneja¹, Jade Jones², Stefania Pittaluga³, Irina Maric⁴, Mohammed Farooqui¹, Inhye E Ahn¹, Adrian Wiestner¹, Clare Sun¹

Affiliations

¹ a Hematology Branch , National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda , MD , USA.
² b Division of Cancer Medicine , MD Anderson Cancer Center , Houston , TX , USA.
³ c Laboratory of Pathology , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
⁴ d Department of Laboratory Medicine , Clinical Center National Institutes of Health , Bethesda , MD , USA.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Biomarkers
Biopsy
Cell Transformation, Neoplastic*
Hodgkin Disease / diagnosis
Hodgkin Disease / etiology*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
Male
Middle Aged
Multimodal Imaging / methods
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*

Substances

Antineoplastic Agents
Biomarkers
Protein Kinase Inhibitors
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human

Grants and funding